Pemgarda™

Understanding Pemgarda™
Pemgarda™ (pemivibart) is a monoclonal antibody designed to provide passive immunity against COVID-19 by targeting and neutralizing the virus. It is intended for pre-exposure prophylaxis in individuals who are moderately to severely immunocompromised and may not mount an adequate immune response to vaccination.

How Pemgarda™ Works:

• Binds to the spike protein of SARS-CoV-2, preventing the virus from entering and infecting human cells.

• Provides immediate, passive protection by delivering ready-made antibodies rather than relying on the body’s own immune response.

• Reduces the risk of COVID-19 infection in high-risk individuals, offering an added layer of defense.

• Especially beneficial for patients with compromised immune systems who remain vulnerable despite vaccination.

FDA Approval:
2024 – Authorized under Emergency Use Authorization (EUA) for pre-exposure prevention of COVID-19 in immunocompromised individuals.

For more information, please visit the Pemgarda™ patient website. Speak with your healthcare provider to determine if Pemgarda™ is the right option for your protection.